Compare Hasbro, Inc. (HAS) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs IDEXX Laboratories, Inc. — how do they compare? Hasbro, Inc. trades at $93.01 (market cap $13.05B), while IDEXX Laboratories, Inc. trades at $520.41 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.1× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays a 3.03% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| HAS | IDXX | |
|---|---|---|
Market Cap | $13.05B | $40.43B |
Volume | 1,207,655 | 692,164 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $766.68 |
52-Week Low | $70.95 | $504.70 |
Typical Hold Time | 97 Days | 46 Days |
Enterprise Value | $15.24B | $41.32B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $90.75, down 0.31% on the day, with strong technical momentum showing bullish moving average signals and key support at $90. The company demonstrates robust profitability with 64.41% gross margins and has beaten earnings estimates for three consecutive quarters, though 2025 showed a net loss of $322.4 million. Analyst consensus remains positive with a $107.60 price target and no sell ratings among 33 analysts.
Outlook remains constructive with projected 2026 revenue growth to $5.0B and net income of $794M, supported by Magic: The Gathering's strong performance. Key risks include high debt levels at 59.09% debt-to-asset ratio and competitive pressures in the toy industry. The stock offers 18.5% upside to consensus target with institutional ownership showing mixed positioning.
IDEXX Laboratories (IDXX) trades at $517.47, up 2.13% with strong earnings momentum after beating Q2 2026 estimates. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and expanded diagnostic platforms highlight growth initiatives, while analyst consensus remains bullish with a $665 price target representing 28.5% upside potential.
The outlook remains positive given consistent earnings beats and expanding veterinary diagnostics market share. Key risks include FX headwinds, weaker U.S. vet visits, and premium valuations at 36x P/E. Institutional ownership trends show mixed activity with recent insider selling, but long-term growth drivers in pet healthcare innovation support the bullish analyst stance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
